Quantcast

Global Anticoagulants Reversal Drugs Market Covering Key Players & Their Competitive Strategies, 2019: Analysis & Outlook Through 2018-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Anticoagulants Reversal Drugs Market Size, Market Share, Application
Analysis, Regional Outlook, Growth Trends, Key Players, Competitive
Strategies and Forecasts, 2018 to 2026”
report has been added
to ResearchAndMarkets.com’s offering.

The global anticoagulants reversal drugs market expected to expand at a
CAGR of 15.3% from 2018 to 2026, owing to the approval of blockbuster
drugs in recent years and strong pipeline driving the market.

The U.S. Food and Drug Administration has designated Andexxa (the most
recently approved drug for factor Xa inhibitors) as an orphan drug and
tagged under the accelerated approval process. European Medicines Agency
is also positive to grant approval for andexanet alfa, with Committee
for Medicinal Products for Human Use (CMPH) reviewing the application.

Idarucizumab, approved in 2015 for an antidote for dabigatran during
atrial fibrillation, is currently under clinical trials for multiple
conditions such as hemorrhage and stroke. Thus strong pipeline and
governmental initiatives will drive the market for anticoagulant
reversal drugs market.

Drugs type such as prothrombin complex concentrates, Vitamin K,
desmopressin which were earlier preferred for containing emergency
situation will demonstrate sluggish growth due to the launch of novel
drugs with better efficacy and quicker effect. However, high prices of
patented drugs would act as a growth barrier in emerging economies.

In terms of geography, North America held the largest share in the
global anticoagulant reversal drugs market owing to increased approvals
and increasing research and development by major pharmaceutical
companies in the region. Europe also held a significant share in the
global market attributable to product approvals. The growing incidence
of uncontrollable bleeding episodes and usage of anticoagulants will
further drive the market in North America and Europe.

The U.S. emerged as the largest country-level market due to efficient
reimbursement scenario of for drugs, a high cost of the recently
approved drugs and accelerated drug approval initiative by U.S. Food and
Drug Administration (FDA) to drive the market.

The Asia Pacific is set to grow at the fastest rate during the forecast
period, driven by rising patient population for diseases such as atrial
fibrillation, strokes, and other cardiopulmonary diseases. Ongoing
trials in the region will further stimulate market growth in the region.

The key players currently engaged in anticoagulant reversal drugs market
include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health
Companies, Inc., CSL Behring Limited, Octapharma AG, Portola
Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc., and Ferring
Pharmaceuticals.

Key Market Movements

    • Strong pipeline for anticoagulant reversal drugs in North America and
      Europe to drive the market during the forecast period
    • Growing research and development by pharmaceutical players further
      boost market growth
    • A rising incidence of uncontrollable bleeding episodes and emergency
      situation due to the use of anticoagulants

Topics Covered

Chapter 1. Preface

1.1. Report Description

1.2. Research Scope

1.3. Research Methodology

1.4. Market Segmentation

Chapter 2. Executive Summary

2.1. Global Anticoagulant Reversal Drugs Market Portraiture

2.2. Global Anticoagulant Reversal Drugs Market, by Drug Class, 2017
(US$ Mn)

2.3. Global Anticoagulant Reversal Drugs Market, by Geography, 2017 (US$
Mn)

Chapter 3. Anticoagulant Reversal Drugs: Market Dynamics and
Outlook

3.1. Market Overview

3.2. Drivers

3.3. Challenges

3.4. Opportunities

3.5. Attractive Investment Proposition, by Geography, 2017

3.6. Competitive Analysis: Global Anticoagulant Reversal Drugs Market,
by Key Players, 2017

Chapter 4. Global Anticoagulant Reversal Drugs Market, by Drug
Class, 2016-2026 (US$ Mn)

4.1. Overview

4.2. Prothrombin Complex Concentrates (PCC)

4.3. Vitamin K

4.4. Protamine

4.5. Tranexmic Acid

4.6. Desmopressin

4.7. Idarucizumab

4.8. Andexxa

4.9. Pipeline Analysis

4.9.1. Phase III Drugs

4.9.1.1. Octaplex

4.9.2. Phase I and II Drugs (Tabular Representation)

Chapter 5. Global Anticoagulant Reversal Drugs Market, by
Geography, 2016-2026 (US$ Mn)

5.1. North America Anticoagulant Reversal Drugs Market Analysis,
2016-2026

5.2. Europe Anticoagulant Reversal Drugs Market Analysis, 2016-2026

5.3. Asia Pacific Anticoagulant Reversal Drugs Market Analysis, 2016-2026

5.4. Latin America Anticoagulant Reversal Drugs Market Analysis,
2016-2026

5.5. Middle East & Africa Anticoagulant Reversal Drugs Market, 2016-2026

Chapter 6. Company Profiles

6.1. Boehringer Ingelheim GmbH

6.2. Fresenius Kabi AG

6.3. Pfizer Inc.

6.4. Bausch Health Companies Inc.

6.5. Amneal Pharmaceuticals Inc.

6.6. CSL Behring Limited

6.7. Octapharma AG

6.8. Portola Pharmaceuticals Inc.

6.9. Perosphere Pharmaceuticals Inc.

6.10. Ferring Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/9rdpv8

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs

Read the full article

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.